Payment overview · 2025
General Payments
$170.44
7 reported records · 3 companies
Healthcare provider profile · identity verified
William P Morris, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEEDS, AL · NPI 1073627121
Verified facts
What the public records show
CMS Open Payments records show William P Morris, M.D. received $170.44 in general payments during 2025 across 7 reported records.
Novo Nordisk Inc accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.89 | 65.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.43 | 26.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.12 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.44 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.35 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.35 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $45.43 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 911 | 274 |
| Atorvastatin Calcium | Atorvastatin Calcium | 820 | 224 |
| Pantoprazole Sodium | Pantoprazole Sodium | 697 | 195 |
| Gabapentin | Gabapentin | 592 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 148 |
| Lisinopril | Lisinopril | 530 | 169 |
| Simvastatin | Simvastatin | 458 | 128 |
| Trazodone Hcl | Trazodone Hcl | 429 | 107 |
| Metformin Hcl | Metformin Hcl | 425 | 136 |
| Omeprazole | Omeprazole | 399 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 109 |
| Losartan Potassium | Losartan Potassium | 370 | 97 |
| Pravastatin Sodium | Pravastatin Sodium | 354 | 98 |
| Carvedilol | Carvedilol | 337 | 86 |
| Furosemide | Furosemide | 337 | 110 |
| Meloxicam | Meloxicam | 336 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 332 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 312 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 94 |
| Tizanidine Hcl | Tizanidine Hcl | 269 | 118 |
| Glimepiride | Glimepiride | 262 | 86 |
| Montelukast Sodium | Montelukast Sodium | 259 | 80 |
| Buspirone Hcl | Buspirone Hcl | 233 | 61 |
| Eliquis | Apixaban | 231 | 36 |
| Mirtazapine | Mirtazapine | 225 | 65 |
| Allopurinol | Allopurinol | 217 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 66 |
| Potassium Chloride | Potassium Chloride | 204 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 200 | 64 |
| Sertraline Hcl | Sertraline Hcl | 197 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 75 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 188 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 43 |
| Methylprednisolone | Methylprednisolone | 170 | 148 |
| Ibuprofen | Ibuprofen | 166 | 56 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 162 | 44 |
| Torsemide | Torsemide | 162 | 49 |
| Ozempic | Semaglutide | 157 | 31 |
| Clonidine Hcl | Clonidine Hcl | 155 | 40 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 146 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 145 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 35 |
| Metformin Hcl Er | Metformin Hcl | 142 | 38 |
| Celecoxib | Celecoxib | 137 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 34 |
| Spironolactone | Spironolactone | 127 | 35 |
| Januvia | Sitagliptin Phosphate | 121 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 119 | 100 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 27 |
| Irbesartan | Irbesartan | 116 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 116 | 32 |
| Naproxen | Naproxen | 114 | 43 |
| Jardiance | Empagliflozin | 112 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 110 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 23 |
| Atenolol | Atenolol | 103 | 34 |
| Glipizide Er | Glipizide | 95 | 27 |
| Memantine Hcl | Memantine Hcl | 94 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 93 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 92 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 28 |
| Baclofen | Baclofen | 89 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 40 |
| Famotidine | Famotidine | 85 | 26 |
| Methocarbamol | Methocarbamol | 85 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 85 | 71 |
| Meclizine Hcl | Meclizine Hcl | 81 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 16 |
| Cefdinir | Cefdinir | 72 | 60 |
| Colchicine | Colchicine | 72 | 24 |
| Azithromycin | Azithromycin | 69 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 68 | 21 |
| Lovastatin | Lovastatin | 68 | 17 |
| Valsartan | Valsartan | 67 | 15 |
| Mounjaro | Tirzepatide | 65 | 13 |
| Megestrol Acetate | Megestrol Acetate | 64 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 14 |
| Alprazolam | Alprazolam | 62 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 15 |
| Levetiracetam | Levetiracetam | 61 | 12 |
| Alendronate Sodium | Alendronate Sodium | 60 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 60 | 17 |
| Levofloxacin | Levofloxacin | 58 | 49 |
| Nifedipine Er | Nifedipine | 58 | 17 |
| Benazepril Hcl | Benazepril Hcl | 57 | 20 |
| Fluconazole | Fluconazole | 57 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 41 |
| Donepezil Hcl | Donepezil Hcl | 52 | 17 |
| Lansoprazole | Lansoprazole | 52 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 51 | 13 |
| Primidone | Primidone | 51 | 17 |
| Xarelto | Rivaroxaban | 51 | 11 |
| Glipizide | Glipizide | 50 | 14 |
| Prednisone | Prednisone | 49 | 37 |
| Chlorthalidone | Chlorthalidone | 48 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 48 | suppressed |
| Topiramate | Topiramate | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 34 |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Bumetanide | Bumetanide | 44 | 14 |
| Indapamide | Indapamide | 44 | 14 |
| Pregabalin | Pregabalin | 44 | suppressed |
| Lactulose | Lactulose | 42 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Felodipine Er | Felodipine | 41 | suppressed |
| Linzess | Linaclotide | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 13 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Valacyclovir | Valacyclovir Hcl | 40 | 12 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 30 |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 24 |
| Nitroglycerin | Nitroglycerin | 32 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 29 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 31 | 20 |
| Metronidazole | Metronidazole | 30 | 28 |
| Fosinopril Sodium | Fosinopril Sodium | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 27 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 26 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Etodolac | Etodolac | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 15 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 14 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 14 | 12 |
| Risperidone | Risperidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.44 · 7 records | Novo Nordisk Inc | Ozempic, Rybelsus, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error